RESEARCH - Short-term efficacy of a novel oral tyrosine kinase inhibitor demonstrated in RA

[Guest guest]

Short-Term Efficacy of a Novel Oral Tyrosine Kinase Inhibitor

Demonstrated in Rheumatoid Arthritis

s Hopkins Arthritis Center

Arthritis News

by Jon Giles, MD

Tyrosine Kinase

Intracellular signaling mechanisms relay cell signals from membrane

bound receptors to the nucleus, where transcription of DNA initiates

an effector response. In inflammatory cells, the effector response

helps to drive the initiation and propagation of inflammatory

diseases, such as rheumatoid arthritis (RA). Thus, inhibiting key

intracellular signals may be a treatment for RA. Here, Weinblatt et

al (Arthritis Rheum 2008; 58(11):3309) report results of the efficacy

and safety of an inhibitor of one such intracellular signaling

mediator, spleen tyrosine kinase (Syk).

*******************************************************

Read the full article here:

http://www.hopkins-arthritis.org/arthritis-news/2008/Short-Term-Efficacy-of-a-No\

vel-Oral-Tyrosine-Kinase-Inhibitor-Demonstrated-in-Rheumatoid-Arthritis.html

Not an MD